Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 36

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 36
---
 approval of product candidates;
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   the outcome, costs and timing of seeking and obtaining regulatory approvals from the FDA, EMA, the MHRA, the MHLW/PMDA, and other comparable regulatory authorities;
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   whether our collaboration partners continue to collaborate with us on the development and commercialization of our product candidates;
------------------------------------------------------------------------------------------------------------------------------------------

●   the number of product candidates and indications that we pursue, whether developed internally or in-licensed;
-----------------------------------------------------------------------------------------------------------------

●   the timing and costs associated with manufacturing our product candidates for clinical trials and other studies and, if approved, for commercial sale;
----------------------------------------------------------------------------------------------------------------------------------------------------------

●   our need to expand our development activities and, potentially, our research activities;
--------------------------------------------------------------------------------------------

●   the timing and costs associated with establishing sales and marketing capabilities;
---------------------------------------------------------------------------------------

●   the costs associated with our future product sales, marketing, commercial manufacturing, and distribution activities;
-------------------------------------------------------------------------------------------------------------------------

●   the costs associated with adding new decentralized manufacturing units our cell therapy product candidates;
---------------------------------------------------------------------------------------------------------------

●   market acceptance of any approved product candidates;
---------------------------------------------------------

●   the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies;
---------------------------------------------------------------------------------------------------------------------------

●   the cost to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
​
25

with licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
------------------------------------------------------------------------------------------------------------------

●   the extent to which we may be required to pay milestone or other payments under our in-license agreements and the timing of such payments;
----------------------------------------------------------------------------------------------------------------------------------------------

●   our need and ability to hire additional management, development and scientific personnel; and
-------------------------------------------------------------------------------------------------

●   our need to implement additional internal systems and infrastructure, including financial and reporting systems.
--------------------------------------------------------------------------------------------------------------------
​
Some of these factors are outside of our control. Based upon our current expected level of operating expenditures and our existing financial investments and cash and cash equivalents, we believe that we will be able to fund our operating expenses and capital expenditure requirements for the coming years. This period could be shortened, but not below a period of 12 months, if there are any significant increases beyond our expectations in spending on development programs or more rapid progress of development programs than anticipated. Accordingly, we expect that we could need to raise additional funds in the future. Additional funding may not be available to us on acceptable terms, or at